Perampanel (PER) is a new antiseizure medication that inhibits the α-amino-3-hydroxy-5-
methyl-4-isoxazole-propionic acid (AMPA) class of glutamate receptors. It is important for …

Aim There are few reports on the tolerability and efficacy of perampanel, a new antiepileptic
drug with a novel mechanism of action, in children and adolescents. We aimed to describe …

PROVE is a retrospective, phase IV study assessing retention, dosing, efficacy, and safety of
perampanel when administered to patients during routine clinical care. We report an interim …

Study 232, an open-label pilot study with an extension phase, evaluated the
pharmacokinetics and preliminary safety/tolerability and efficacy of adjunctive perampanel …

Objective This article aims to report the first clinical experiences concerning effectiveness
and tolerability of perampanel (PER) in a pediatric population with refractory epilepsies …

Introduction Perampanel is an AMPA receptor antagonist recently approved for the treatment
of partial and generalized epilepsies with tonic–clonic seizures as an add-on therapy …

Purpose To evaluate the efficacy and tolerability of Perampanel (PER) in children and
adolescents with refractory epilepsies in daily clinical practice conditions. Patients and …

Abstract ELEVATE (Study 410; NCT03288129) is the first prospective, multicenter, open-
label, Phase IV study of perampanel as monotherapy or first adjunctive therapy in patients …

Purpose There is limited data on the use of perampanel in children under 12 years of age.
We evaluated the efficacy and tolerability of adjunctive perampanel treatment in children …

Objective To evaluate the effectiveness and safety of perampanel (PER) monotherapy (MT)
or add‐on therapy (AT) in Chinese children with epilepsy, as well as to evaluate the data …